Editas Q3 Loss Narrows; First Dosing In EDIT-401 Cholesterol Trial On Track For 2026

(RTTNews) - Editas Medicine, Inc. (EDIT) on Monday reported a narrower third-quarter loss as collaboration revenue incre...

By Dhallo News · November 9, 2026 at 8:57 PM IST

(RTTNews) - Editas Medicine, Inc. (EDIT) on Monday reported a narrower third-quarter loss as collaboration revenue increased. The gene-editing company also said it remains on track to begin dosing patients in its first clinical trial of EDIT-401 by year-end. Third-Quarter 2026

SOURCE: Nasdaq

ORIGINAL REPORT: Click here

DHALLO EDITORIAL STATUS: Aggregated & reviewed

Have feedback on this article?Report error or suggestion

Editas Q3 Loss Narrows; First Dosing In EDIT-401 Cholesterol Trial On Track For 2026

Read More from Markets

SPSB, MUZ: Big ETF Outflows

Kamada Ltd. Reports Record First Nine Months 2026 Financial Results and Declares Cash Dividend of $0.14 Per Share

Wall Street bounces back from AI sell-off, Nasdaq rallies over 3%, but Nvidia plunges 9% on Jensen Huang controversy

5 minutes. The news that matters.